Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 1/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.41 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.41 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | FGF1 | P05230 | 1/20 | 0.38 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18390837 | 1.00 | PYGB (0.43) | PYGBLGALS8LGALS1LGALS3LGALS9 | |
| SCHEMBL78631 | 1.00 | PYGB (0.43) | PYGBLGALS8LGALS1LGALS3LGALS9 | |
| SCHEMBL6157450 | 1.00 | PYGB (0.43) | PYGBLGALS8LGALS1LGALS3LGALS9 | |
| SCHEMBL767465 | 1.00 | PYGB (0.43) | PYGBLGALS8LGALS1LGALS3LGALS9 | |
| SCHEMBL13446418 | 1.00 | PYGB (0.43) | PYGBLGALS8LGALS1LGALS3LGALS9 | |
| SCHEMBL767424 | 1.00 | PYGB (0.43) | PYGBLGALS8LGALS1LGALS3LGALS9 | |
| SCHEMBL14479870 | 1.00 | PYGB (0.43) | PYGBLGALS8LGALS1LGALS3LGALS9 | |
| SCHEMBL505006 | 1.00 | PYGB (0.43) | PYGBLGALS8LGALS1LGALS3LGALS9 | |
| SCHEMBL1985946 | 1.00 | PYGB (0.43) | PYGBLGALS8LGALS1LGALS3LGALS9 | |
| SCHEMBL248110 | 1.00 | PYGB (0.43) | PYGBLGALS8LGALS1LGALS3LGALS9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020205846-A1 | INHIBITORS OF ALDOSE REDUCTASE | APPLIED THERAPEUTICS INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-8952217-B2 | Process for decreasing verbascose in a plant by expression of a chloroplast-targeted fimD protein | METANOMICS GMBH (DE) | 2015-02-10 | — | — | US | disclosed |
| US-20140325709-A1 | PROCESS FOR THE PRODUCTION OF FINE CHEMICALS | METANOMICS GMBH (DE) | 2014-10-30 | — | — | US | disclosed |
| EP-2573188-A2 | Process for the production of fine chemicals | Metanomics GmbH (DE) | 2013-03-27 | — | — | EP | disclosed |
| EP-2368905-A2 | Process for the control of production of fine chemicals | Metanomics GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
| EP-2194140-A2 | Process for the production of fine chemicals | Metanomics GmbH (DE) | 2010-06-09 | — | — | EP | disclosed |
| US-20100068692-A1 | ANTIFREEZE GLYCOPROTEIN ANALOGUES AND USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2010-03-18 | — | — | US | disclosed |
| CN-101675069-A | Method for producing fine chemicals | METANOMICS GMBH | 2010-03-17 | — | — | CN | disclosed |
| EP-2096177-A2 | Process for the production of lutein | Metanomics GmbH (DE) | 2009-09-02 | — | — | EP | disclosed |
| CN-101421412-A | Process for the production of fine chemicals | METANOMICS GMBH (DE) | 2009-04-29 | — | — | CN | disclosed |
| EP-1974049-A2 | PROCESS FOR THE CONTROL OF PRODUCTION OF FINE CHEMICALS | Metanomics GmbH (DE) | 2008-10-01 | — | — | EP | disclosed |
| EP-1871883-A1 | PROCESS FOR THE PRODUCTION OF FINE CHEMICALS | Metanomics GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| US-20070118916-A1 | Process for the production of fine chemicals | METANOMICS GMBH (DE) | 2007-05-24 | — | — | US | disclosed |
| EP-1765857-A2 | PROCESS FOR THE PRODUCTION OF FINE CHEMICALS | Metanomics GmbH (DE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006092449-A2 | PROCESS FOR THE PRODUCTION OF FINE CHEMICALS | METANOMICS GMBH (DE) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068692-A1 | ANTIFREEZE GLYCOPROTEIN ANALOGUES AND USES THEREOF | SRRM2, MSR1, CD59 | PYGB 1509/4885LGALS8 566/4885LGALS1 248/4885 |
| US-20070118916-A1 | Process for the production of fine chemicals | POLRMT, POLI, POLM | PYGB 908/4885LGALS8 4018/4885LGALS1 4118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.